全球卫生治理下的《与贸易相关的知识产权协定》中弹性条款与药品可及性问题研究  

Flexible clauses in the TRIPS agreement and access to essential medicine from the perspectives of global health governance

作　　者：王丹[1] 赵英希 唐昆[2] 

机构地区：[1]北京大学医学人文研究院,北京100191 [2]北京大学公共卫生学院全球卫生系,北京100191

出　　处：《中国新药杂志》2017年第9期976-984,共9页Chinese Journal of New Drugs

摘　　要：在全球卫生治理中,如何平衡药品研发技术创新与药品可及性之间的问题由来已久,发达国家和发展中国家在这一议题上的利益界定与谈判策略分歧也逐渐加大。本文通过分析弹性条款以及发达国家与发展中国家持有不同立场,认为中国在参与全球卫生治理中,充分使用《与贸易相关的知识产权协定》(TRIPS协议)下的弹性条款,维护发展中国家的利益,是必要的选择。In global health governance, the balance between accessibility to essential medicines and the research and development of pharmaceuticals has been a long-standing issue. Because of the diverged national interests, the developed and developing countries pursue different strategies in their negotiations at various global health governance platforms. This study examines the flexible clauses in the TRIPS agreement and the different standpoints of both developed and developing countries, and proposes that China should take full advantage of the flexible clauses in its global health governance to protect the interests of developing countries.

关 键 词：TRIPS协议 弹性条款 药品可及性 全球卫生治理 

分 类 号：R286.91[医药卫生—中药学]